Concord Biotech Limited (BOM: 543960)

Market Cap	222.76B
Revenue (ttm)	10.86B
Net Income (ttm)	3.28B
Shares Out	n/a
EPS (ttm)	31.35
PE Ratio	67.93
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,840
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1,326.90 - 2,658.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 10, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,377
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2023, Concord Biotech's revenue was 10.17 billion, an increase of 19.20% compared to the previous year's 8.53 billion. Earnings were 3.08 billion, an increase of 28.33%.